Vitronectin and substitution of a β-strand 5A lysine residue potentiate activity-neutralization of PA inhibitor-1 by monoclonal antibodies against α-helix F

Thrombosis and Haemostasis

Volumn 83, Issue 5, 2000, Pages 742-751

  Schousboe, Susanne L ^c   Egelund, Rikke ^c   Kirkegaard, Tove ^c   Preissner, Klaus T ^a   Rodenburg, Kees W ^c   Andreasen, Peter A ^b  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b AARHUS UNIVERSITY   (Denmark)

^c NONE

Author keywords

Cancer; Serine proteinases; Serpins; Thrombosis

Indexed keywords

EPITOPE; LYSINE; MONOCLONAL ANTIBODY; PLASMINOGEN ACTIVATOR INHIBITOR 1; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; VITRONECTIN;

AMINO ACID SUBSTITUTION; ARTICLE; CANCER; COMPLEX FORMATION; HUMAN; PRIORITY JOURNAL; THROMBOSIS;

EID: 0009448606     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1613903     Document Type: Article

References (56)

1. Potempa J, Korzus E, Travis J. The serpin superfamily of proteinase inhibitors: structure, function, and regulation. J Biol Chem 1994; 269: 15957-60.
2. 1-antitrypsin for structure and functions of serpins. Biochemistry 1989; 28: 8951-66.
3. Carrell RW, Stein PE. The biostructural pathology of the serpins: critical functions of sheet opening mechanism. Biol Chem Hoppe-Seyler 1996; 377: 1-17.
4. Gettins PG, Patson PA, Schapira M. The role of conformational change in serpin structure and function. Bioessays 1993; 15: 461-7.
5. Gils A, Declerck PJ. Structure-function relationships in serpins: current concepts and controversies. Thromb Haemost 1998; 80: 531-41.
6. Wright HT, Scarsdale JN. Structural basis for serpin inhibitor activity. Proteins: Struct Func Gen 1995; 22: 210-25.
7. Engh RA, Huber R, Bode W, Schulze AJ. Divining the serpin inhibition mechanism: a suicide substrate 'springe'? Trends in Biotechnol 1995; 13: 503-10.
8. Aertgeerts K, De Ranter CJ, Booth NA, Declerck PJ. Rational design of complex formation between plasminogen activator inhibitor-1 and its target proteinases. J Struct Biol 1997; 113: 236-42.
9. Wilczynska M, Fa M, Karolin J, Ohlsson PI, Johansson LB, Ny T. Structural insights into serpin-protease complexes reveal the inhibitory mechanism of serpins. Nature Struct Biol 1997; 4: 354-7.
10. Lawrence DA, Ginsburg D, Day DE, Berkenpas MB, Verhamme IM, Kvassman JO, Shore JD. Serpin-protease complexes are trapped as stable acyl-enzyme intermediates. J Biol Chem 1995; 270: 25309-12.
11. Stratikos E, Gettins PGW. Major proteinase movement upon stable serpin-protease complex formation. Proc Natl Acad Sci USA 1997; 94: 453-8.
12. 1-proteinase inhibitor Pittsburgh. J Biol Chem 1998; 273: 15582-9.
13. Stratikos E, Gettins PGW. Formation of the covalent serpin-proteinase complex involves translocation of the proteinase by more than 70 A and full insertion of the reactive centre loop into β-sheet A. Proc Natl Acad Sci USA 1999; 96: 4808-13.
14. Wilczynska M, Fa M, Ohlsson PI, Ny T. The inhibition mechanism of serpins. Evidence that the mobile reactive centre loop is cleaved in the native protease-inhibitor complex. J Biol Chem 1995; 270: 29652-5.
15. Egelund R, Rodenburg KW, Andreasen PA, Rasmussen MS, Guldberg RE, Petersen TE. An ester bond linking a fragment of a serine proteinase to its serpin inhibitor. Biochemistry 1998; 37: 6375-9.
16. Andreasen PA, Georg B, Lund LR, Riccio A, Stacey SN. Plasminogen activator inhibitors: hormonally regulated serpins. Mol Cell Endocrinol 1990; 68: 1-19.
17. Andreasen PA, Kjøller L, Christensen L, Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis. A review, Int J Cancer 1997; 72: 1-22.
18. Declerck PJ, Juhan-Vague I, Felez J, Wiman B. Pathophysiology of fibrinolysis. J Intern Med 1994; 236: 425-32.
19. Aertgeerts K, De Bondt HL, De Ranter CJ, Declerck PJ. Mechanisms contributing to the conformational and functional flexibility of plasminogen activator inhibitor-1. Nature Struct Biol 1995; 2: 891-7.
20. Aertgeerts K, De Bondt HL, De Ranter CJ, Declerck PJ. A model of the reactive form of plasminogen activator inhibitor-1. J Struct Biol 1994; 113: 239-45.
21. Sharp AM, Stein PE, Pannu NS, Carrell RW, Berkenpas MB, Ginsburg D, Lawrence DA, Read RJ. The active conformation of plasminogen activator inhibitor 1, a target for drugs to control fibrinolysis and cell adhesion. Structure 1999; 7: 111-8.
22. Mottonen J, Strand A, Symersky J, Sweet RM, Danley DE, Geoghegan KF, Gerard RD, Goldsmith EJ. Structural basis of latency in plasminogen activator inhibitor-1. Nature 1992; 355: 270-3.
23. Preissner KT, Jenne D. Structure of vitronectin and its biological role in haemostasis. Thromb Haemost 1991; 66: 123-32.
24. Deng G, Royle G, Seiffert D, Loskutoff D. The PAI-1/vitronectin interaction: two cats in a bag? Thromb Haemost 1995; 74: 66-70.
25. van Meijer M, Gebbink RK, Preissner KT, Pannekoek H. Determination of the vitronectin binding site on plasminogen activator inhibitor 1 (PAI-1), FEBS Lett 1994; 352: 342-6.
26. Lawrence DA, Berkenpas MB, Palaniappan S, Ginsburg D. Localization of vitronectin binding domain in plasminogen activator inhihitor-1. J Biol Chem 1994; 269: 15223-8.
27. Padmanabhan J, Sane DC. Localization of a vitronectin binding region of plasminogen activator inhibitor-1. Thromb Haemost 1995; 73: 829-34.
28. Fa M, Karolin J, Aleshkov S, Strandberg L, Johansson LB-Å, Ny T. Time-resolved polarized fluorescence spectroscopy studies of plasminogen activator inhibitor type-1: Conformational changes of the reactive centre upon interactions with target proteases, vitronectin and heparin. Biochemistry 1995; 34: 13833-40.
29. Gibson A, Bahuraj K, Day DE, Verhamme I, Shore JD, Peterson CB. The use of fluorescent probes to characterize conformational changes in the interaction between vitronectin and plasminogen activator inhibitor-1. J Biol Chem 1997; 272: 5112-21.
30. Keijer J, Linders M, van Zonneveld A-J, Ehrlich HJ, de Boer J-P, Pannekoek H. The interaction of plasminogen activator inhibitor 1 with plasminogen activators (tissue-type and urokinase-type) and fibrin: Localization of interaction sites and physiologic relevance. Blood 1991; 78: 401-9.
31. Debrock S, Declerck PJ. Neutralization of plasminogen activator inhibitor-1 inhibitory properties: identification of two different mechanisms. Biochim Biophys Acta 1997; 1337: 257-66.
32. Debrock S, Declerck PJ. Cloning of a single chain variable fragment (scFv) switching active plasminogen activator inhibitor-1 to substrate. Gene 1997; 189: 83-8.
33. Debrock S, Declerck PJ. Identification of a functional epitope in plasminogen activator inhibitor-1, not localized in the reactive centre loop. Thromb Haemost 1998; 79: 597-601.
34. Kirkegaard T, Jensen S, Schousboe SL, Petersen HH, Egelund R, Andreasen PA, Rodenhurg KW. Engineering of conformations of plasminogen activator inhihitor-1. A crucial role of β-strand 5A residues in the transition of active form to latent and substrate forms. Eur J Biochem 1999; 263: 577-86.
35. Munch M, Heegaard CW, Andreasen PA. Interconversions between active, inert and subsrate forms of denatured/refolded type-1 plasminogen activator inhibitor. Biochim Biophys Acta 1993; 1202: 29-37.
36. 2-macroglobulin receptor/low-density lipoprotein receptor-related protein and very-low-density lipoprotcin receptor involves basic residues in the inhibitor. Biochem J 1998; 329: 55-63.
37. Andreasen PA, Riccio A, Welinder KG, Douglas R, Sartorio R, Nielsen LS, Oppenheimer C, Blasi F, Danø K. Plasminogen activator inhibitor type 1: reactive centre and amino-terminal heterogeneity, determined by protein and cDNA sequencing. FEBS Lett 1986; 209: 213-8.
38. Stockmann A, Hess S, Declerck P, Timpl R, Preissner KT. Multimeric vitronectin. Identification and characterization of conformation-dependent self-association of the adhesive protein. J Biol Chem 1993; 268: 22874-82.
39. Nielsen LS, Andreasen PA, Grøndahl-Hansen J, Huang J-Y, Kristensen P, Danø K. Monoclonal antibodies to human 54,000-molecular-weight plasminogen-activator inhibitor from fibrosarcoma cells-inhibitory neutralization and one-step affinity purification. Thromb Haemost 1986; 55: 206-12.
40. Munch M, Heegaard CW, Jensen PH, Andreasen PA. Type-1 inhibitor of plasminogen activator. Distinction between latent, active and reactive centre-cleaved forms with thermal stability and monoclonal antibodies. FEBS Lett 1991; 295: 102-6.
41. 2-macroglubulin receptor in human breast carcinomas. Int J Cancer 1996; 66: 441-52.
42. Shulman M, Wilde CD, Köhler G. A better cell line for making hybridomas secreting specific antibodies. Nature 1978; 276: 269-70.
43. Nielsen LS, Hansen JG, Andreasen PA, Skriver L, Danø K, Zeuthen J. Monoclonal antibody to human 66,000 molecular weight plasminogen activator from melanoma cells. Specific enzyme inhibition and one-step purification. EMBO J 1983; 2: 115-9.
44. Andreasen PA, Nielsen LS, Kristensen P, Grøndahl-Hansen J, Skriver L, Danø K. Plasminogen activator inhibitor from human fibrosarcoma cells binds urokinase-type plasminogen activator, but not its proenzyme. J Biol Chem 1986; 261: 7644-51.
45. Egelund R, Schousboe SL, Sottrup-Jensen L, Rodenburg KW, Andreasen PA. Type-1 plasminogen activator inhibitor. Conformational differences between latent, active, reactive-centre-cleaved and plasminogen-activator-complexed forms, as probed by proteolytic susceptibility. Eur J Biochem 1997; 248: 775-85.
46. Kraulis PJ. MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures. J Appl Crystallogr 1991; 24: 946-50.
47. Kjøller L, Martensen PM, Sottrup-Jensen L, Justesen J, Rodenburg KW, Andreasen PA. Conformational changes of the reactive centre loop and β-strand 5A accompany temperature-dependent inhibitor-substrate transition of plasminogen activator inhibitor-1. Eur J Biochem 1996; 241: 38-46.
48. Andreasen PA, Egelund R, Jensen S, Rodenburg KW. Solvent effects on activity and conformation of plasminogen activator inhibitor-1. Thromb Haemost 1999; 81: 407-14.
49. Hubbard SJ, Eisenmenger F, Thornton JM. Modeling studies of the change in conformation required for cleavage of limited proteolytic sites. Protein Sci 1994; 3: 757-68.
50. 2-macroglobulin receptor/low density lipoprotein receptor-related protein. Evidence that the urokinase receptor protects pro-urokinase against binding to the endocytic receptor. J Biol Chem 1994; 269: 25668-76.
51. Heegaard CW, Simonsen AC, Oka K, Kjøller L, Christensen A, Madsen B, Ellgaard L, Chan L, Andreasen PA. Very low density lipoprotein receptor binds and mediates endocytosis of urokinase-type plasminogen activator-type-1 plasminogen activator inhibitor complex. J Biol Chem 1995; 270: 20855-61.
52. Bajou K, Noel A, Gerard RD, Masson V, Brunner N, Holst-Hansen C, Skobe M, Fusenig NE, Carmeliet P, Collen D, Foidart JM. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med 1998, 4: 923-8.
53. Juhan-Vague I, Alessi MC. Fibrinolysis and risk of coronary artery disease. Fibrinolysis 1996; 10: 127-36.
54. Urano T, Strandberg L, Johansson LB, Ny T. A substrate-like form of plasminogen-activator-inhibitor type 1. Conversions between different forms by sodium dodecyl sulphate. Eur J Biochem 1992; 209: 985-92.
55. Friederich PW, Levi M, Biemond BJ, Charlton P, Templeton D, van Zonneveld AJ, Bevan P, Pannekoek H, Cate JW. Novel low-molecular-weight inhibitor of PAI-1 (XR5118) promotes endogenous fibrinolysis and reduces postthrombolysis thrombus growth in rabbits. Circulation 1997; 96: 916-21.
56. Björquist P, Ehnehom J, Inghardt T, Hansson L, Lindberg M, Linschoten M, Strömquist M, Deinum J. Identification of the binding site for a low-molecular weight inhibitor of plasminogen activator inhibitor type 1 by site directed mutagenesis. Biochemistry 1998; 37: 1227-34.